Matthew Taylor

Dr. Matthew Taylor

York Health Economics Consortium, York, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
JBJennifer H Barnett
Jennifer H Barnett
LLLily Lewis
Lily Lewis
ABAndrew D Blackwell
Andrew D Blackwell
Matthew TaylorMatthew Taylor
Matthew Taylor
Intervention and treatment in Alzheimer’s disease dementia (AD-dementia) can be cost effective but the majority of patients are not diagnosed in a timely manner. Technology is now available that can enable the earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention in the UK health care system. This study aimed to determine to what extent the timing of an intervention affects its cost-effectiveness.

1 March 2017 in European Stroke Journal
Verified
Journal Article
Open access
AWAlastair Wilson
Alastair Wilson
PBPhilip Mw Bath
Philip Mw Bath
EBEivind Berge
Eivind Berge
Dominique CadilhacDominique Cadilhac
Dominique Cadilhac
MCMatthieu Cuche
Matthieu Cuche
KLKennedy R Lees
Kennedy R Lees
Background and purpose: Cost-of-illness studies often describe a single aggregate cost of a disease state. This approach is less helpful for a condition with a spectrum of outcomes like stroke. The modified Rankin Scale is the most commonly used outcome measure for stroke. We sought to describe the existing evidence on the costs of stroke according to individual modified Rankin Scale categories. This may be useful in future cost effectiveness modelling studies of interventions where cost data have not been collected, but disability outcome is known. Methods: Systematic review of the published literature, searching electronic databases between 2004 and 2015 using validated search filters. Results were screened to identify studies presenting costs by individual modified Rankin Scale categories. Results: Of 17,782 unique identified articles, 13 matched all inclusion criteria. In only four of these studies were costs reported by modified Rankin Scale categories. Most studies included direct medical costs only. Societal costs were assessed in two studies. Overall, studies had a high methodological and reporting quality. The heterogeneity in costing methods used in the identified studies prevented meaningful comparison of the reported cost data. Despite this limitation, the costs consistently increased with greater severity (increasing modified Rankin Scale score). Conclusions: Few cost studies of stroke include information based on stroke recovery measured by individual modified Rankin Scale categories and the existing data are limited. To reliably capture this information, future studies are needed that preferably apply standardised costing methods to promote greater potential for use in cost-effectiveness analyses whereby direct collection of patient-level resource use has not been possible.

1 March 2010 in Applied Health Economics and Health Policy
Verified
Journal Article
Closed access
PDF file
Paul ScuffhamPaul Scuffham
Paul Scuffham
JWJennifer A. Whitty
Jennifer A. Whitty
Matthew TaylorMatthew Taylor
Matthew Taylor
RSRuth C. Saxby
Ruth C. Saxby

1 February 2017 in Value in Health
Verified
Journal Article
Closed access
Matthew TaylorMatthew Taylor
Matthew Taylor
SCSusan Chilton
Susan Chilton
SRSarah Ronaldson
Sarah Ronaldson
HMHugh Metcalf
Hugh Metcalf
JNJytte Seested Nielsen
Jytte Seested Nielsen

1 October 2024 in European Journal of Environment and Public Health
Verified
Journal Article
Open access
PDF file
MPMelissa Pegg
Melissa Pegg
CMChetan Mistry
Chetan Mistry
Erin BarkerErin Barker
Erin Barker
Matthew TaylorMatthew Taylor
Matthew Taylor
Objectives: The aim of this study was to investigate whether it is possible to elicit how United Kingdom (UK) public citizens might trade off human health and environmental outcomes. Methods: Using a representative adult population, a discrete choice experiment (DCE) was conducted on criteria impacting trade-off decisions between human health and environmental outcomes. Respondents were asked to make twelve choices that included four attributes: the impact on UK life expectancy, the impact on biodiversity, the impact on UK carbon emissions and location of environmental impacts. Data were analyzed using a conditional logit regression model. Results: 508 respondents completed the survey. A DCE found UK public citizens are willing to forgo human health to reduce environmental harm. Conclusions: This research demonstrated it is possible to elicit the public’s view about trade-offs between health and the environment. Moreover, the public is willing to forgo human health to reduce environmental impact, propounding the importance of healthcare sustainability.

7 September 2016 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
JHJ. Hahn-Pedersen
J. Hahn-Pedersen
MWMargitta Worm
Margitta Worm
WGW. Green
W. Green
JAJ. Nørgaard Andreasen
J. Nørgaard Andreasen
Matthew TaylorMatthew Taylor
Matthew Taylor
Asthma affects an estimated 300 million people worldwide with the condition associated with significant healthcare utilisation costs and a large impact on patient quality of life. The SQ® HDM SLIT-tablet (ACARIZAX®, Hørsholm, Denmark) is a sublingually administered allergy immunotherapy tablet for house dust mite allergic asthma and allergic rhinitis and has recently been licensed in Europe. To assess the cost-effectiveness of ACARIZAX plus pharmacotherapy versus placebo plus pharmacotherapy in patients with house dust mite allergic asthma that is uncontrolled by inhaled corticosteroids, in a German setting. Eligible patients should also have symptoms of mild to severe allergic rhinitis. A cost utility analysis was undertaken, based on the results of a European phase III randomised controlled trial, in which ACARIZAX was compared with placebo with both treatment groups also receiving pharmacotherapy in the form of inhaled corticosteroids and short-acting β2-agonists. Cost and quality-adjusted life years from the trial were extrapolated over a nine year time horizon and the incremental cost-effectiveness ratio calculated to compare treatment options. ACARIZAX plus pharmacotherapy was estimated to generate 6.16 quality-adjusted life years per patient at a cost of €5658, compared with 5.50 quality-adjusted life years (QALYs) at a cost of €2985 for placebo plus pharmacotherapy. This equated to an incremental cost of €2673, incremental QALYs of 0.66 and an incremental cost-effectiveness ratio (ICER) of €4041. The ICER was, therefore, substantially lower than the €40,000 willingness-to-pay threshold per QALY adopted for the analysis. Deterministic sensitivity analyses indicate the results are most sensitive to the utility score of ACARIZAX patients during years 2 and 3 of treatment. This analysis indicates that ACARIZAX plus pharmacotherapy is cost-effective compared with placebo plus pharmacotherapy for house dust mite allergic asthma patients in Germany. If a disease-modifying effect can be proven the results of this analysis may underestimate the true benefits of ACARIZAX.